diet drug semaglutide Use of new drugs likely to mushroom— Harvard Gazette GLP-1 weight-loss drug popularity reaches
Description
Group one (N=40) was given long-acting basal plus 1.0 mg SC semaglutide

Clinical evidence The SURMOUNT-1 trial found that participants without diabetes lost an average of 22.5% of body weight at the 15 mg dose after 72 weeks

Here is what you actually pay and how and when you pay it

Not all patients are candidates for oral therapy

Diabetes 58 , 16041615, (2009)

NEJM 2017;377:2063-72 NAFLD: progression of disease Liver histology in NAFLD Histology scoring NAS (NAFLD Activity Score), reflects disease activity: unweighted composite of Steatosis (0 to 3) Lobular inflammation (0 to 3) Ballooning (0 to 2) SAF Score: semi-quantitative score of Steatosis (0 to 3) Activity (lobular inflammation + ballooning) = NAS (0 to 8) Fibrosis (0 to 4) Adapted from Chalasani N
